Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma.

J Immunother Cancer · 2022 · PMC8935174 · PMID 35304405

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Differences in PFS and OS with nivolumab plus ipilimumab versus sunitinib did not reach statistical significance when the 213 RNA-seq–evaluable patients were grouped into these five clusters of patients ( online supplemental figure 6 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.